This week, we have conversations with Dr Peter Tummino, president of R&D at Nimbus, and Alex Del Priore, senior vice president, manufacturing at Syngene International Limited.

Interview times:

02:00 Syngene

20:27 Nimbus Therapeutics

Nimbus Therapeutics

Nimbus Therapeutics is perhaps best known for two high-profile deals – Gilead’s $1.2bn acquisition of its NASH program and Takeda’s $4bn acquisition of its TYK2 candidate for psoriasis. NASH and TYK2 are well-known targets that many companies have tried and failed to address over the last four decades. What enables Nimbus to take on these challenging therapeutic areas and succeed?

Nimbus leverages a unique computational chemistry, physics-based d ...